VEGF deficit is involved in endothelium dysfunction in preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Vascular Biology
• Cellular and Molecular Medicine

Background:

• Preeclampsia is a pregnancy complication characterized by hypertension and proteinuria.
• Endothelial dysfunction is a key feature of preeclampsia.
• Vascular Endothelial Growth Factor (VEGF) is crucial for vascular health and angiogenesis.

Purpose of the Study:

• To investigate the association between vascular endothelial growth factor (VEGF) expression and endothelial dysfunction in preeclampsia.
• To determine VEGF levels in preeclampsia patients compared to normotensive controls.
• To explore the functional role of VEGF in endothelial cells.

Main Methods:

• Quantification of VEGF protein and mRNA in placental and serum samples using ELISA and RT-PCR.
• Immunohistochemistry to localize VEGF expression in placental tissue.
• In vitro studies using human umbilical vein endothelial cells (HUVECs) with VEGF inhibition (siRNA) to assess barrier function, proliferation, and nitric oxide (NO) production.

Main Results:

• VEGF was expressed in placental syncytiotrophoblasts and endothelial cells.
• Serum VEGF levels were significantly lower in preeclampsia patients compared to normotensive pregnant women.
• Placental VEGF mRNA levels were paradoxically high in preeclampsia, despite low serum protein.
• VEGF deficiency impaired HUVEC barrier function, reduced proliferation, and decreased NO secretion.
• VEGF administration protected endothelial cells from injury.

Conclusions:

• Decreased serum VEGF levels are associated with endothelial dysfunction in preeclampsia.
• VEGF deficiency appears to be a contributing factor to the pathogenesis of preeclampsia.
• Targeting VEGF may offer therapeutic potential for preeclampsia.